Open an account

Context Therapeutics

CNTX · NASDAQ

$0.2438+$0.0054 (+2.27%)TodayMarket closed ·
Prev close $0.2384

About CNTX

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 15 full-time employees. The company went IPO on 2021-10-20. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.

Employees
15
Headquarters
PHILADELPHIA, Pennsylvania
Listed
Oct 20, 2021
Sector
Health Care
Industry
Pharmaceuticals
Website
contexttherapeutics.com

CNTX key statistics

Market cap
22.40M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
955.73K
Volume
732.86K
Open price
$0.2379
High today
$0.2534
Low today
$0.2277
52 Week high
$3.62
52 Week low
$0.2221

Context Therapeutics (CNTX) at a glance

Context Therapeutics (CNTX) last traded at $0.2438, with a market cap of 22.40M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.2277 and $0.2534. The current price is 7.1% above the day's low and 3.8% below its high.

Volume so far is 732.86K shares, below the average of 955.73K shares a day.

Over the past year Context Therapeutics has ranged from $0.2221 to $3.62, and now sits 1% of the way up that range.

Context Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.15 per share against an estimate of -$0.0941.

The average analyst price target is $4.46, 1730.4% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $4.46
Low
$2.02
Now
$0.2438
High
$6.30

CNTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 32.6% on average.

  1. Q3 FY24: reported -$0.22 per share against an estimate of -$0.1071
  2. Q4 FY24: reported -$0.04 per share against an estimate of -$0.0947
  3. Q1 FY25: reported -$0.05 per share against an estimate of -$0.059
  4. Q2 FY25: reported -$0.09 per share against an estimate of -$0.0624
  5. Q3 FY25: reported -$0.10 per share against an estimate of -$0.0961
  6. Q4 FY25: reported -$0.14 per share against an estimate of -$0.1082
  7. Q1 FY26: reported -$0.09 per share against an estimate of -$0.1197
  8. Q2 FY26: reported -$0.15 per share against an estimate of -$0.0941

CNTX news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Tanya Rawat

    Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move

  • Vandana Singh

    Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

  • Press releaseGlobe Newswire

    Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

  • Press releaseGlobe Newswire

    Context Therapeutics to Present at the Jefferies Global Healthcare Conference

  • Press releaseBusiness Wire

    Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

Similar companies

Companies in the same industry as Context Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.